Open Access
Tableau II.
Résumé des principales études pivotales concernant l’omalizumab dans l’urticaire chronique spontanée.
| Nom de l’étude | N | Durée de l’étude (semaines) | Amélioration du score ISS à la semaine 12 | Amélioration du score UAS7à la semaine 12 | Références | ||
|---|---|---|---|---|---|---|---|
| OMA 300 mg/4 semaines | Placebo | OMA 300 mg/4 semaines | Placebo | ||||
| Asteria I | 319 | 24 | – 9,4 | – 3,63 | – 20,75 | – 8 | [13] |
| Asteria II | 323 | 12 | – 9,8 | – 5,1 | 66 % UAS7 < 6 | 19 % UAS < 6 | [14] |
| Glacial | 336 | 24 | – 8,6 | – 4 | – 19 | – 8,5 | [15] |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.